Blood Pressure Lowering Across CKD Stages: Meta-Analysis Findings
Blood Pressure Lowering Across CKD Stages: Meta-Analysis Findings
Source: ReachMD
May 4, 2026
Meta-analysis published in The Lancet
Key Findings:
* Large individual-participant data meta-analysis including 285,124 participants from 46 randomized trials
* 20.7% had chronic kidney disease (CKD), and 30.2% had type 2 diabetes
* Median follow-up: 4.4 years
* Each 5 mm Hg reduction in systolic BP was associated with ~10% reduction in major cardiovascular events
* Benefit was consistent:
* With or without CKD
* Across CKD stages (including advanced stages)
* Across proteinuria subgroups
* Across baseline BP levels, even <120/70 mm Hg
* Antihypertensive drug classes showed similar relative effects vs placebo, supporting a BP-driven class- benefit
* Overall conclusion:
Cardiovascular benefit of BP lowering is largely preserved across all CKD stages, regardless of renal function severity
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00367-3/fulltext